A Phase 3 interventional study of Treprostinil Palmitil Inhalation Powder and Placebo in Pulmonary Hypertension and Interstitial Lung Disease, sponsored by Insmed Incorporated. Recruiting at 12 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Insmed Incorporated · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 397 studies in Hypertension, Pulmonary with a site in United States — 73 open to participants now, 87 under way, 9 of them phase 3. Hypertension, Pulmonary · United States.
Among the 397 studies in Hypertension, Pulmonary with a site in United States, this one is the 26th largest by planned enrollment of the 286 interventional ones that give a count, is one of 24 that started in 2026, is one of 65 in phase 3, reaches primary completion later than 79 of the 85 other live ones, and was the 377th registered.
1,092 studies on the registry are indexed under Hypertension, Pulmonary; 244 are open to participants now.
Browse Hypertension, Pulmonary studies →73 of the 397 studies in Hypertension, Pulmonary with a site in United States are open now. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18–80
University of California, Davis · Sites in United States
Ages up to 28 days
Tectonic Operating Company, Inc. · Sites in United States, Poland, Romania and 3 more countries
Ages 18–80
35Pharma Inc., a GSK company · Sites in United States
Ages 18+
National Institutes of Health Clinical Center (CC) · Sites in United States
Ages 18–100
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 164 Hypertension, Pulmonary studies recruiting now, 99 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 39 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
397 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 39 · Phase 2 114 · Phase 3 75 · Phase 4 38
First in 1992; this study’s year is marked. 24 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 344 is above the median of 35 across 650 interventional studies indexed under Hypertension, Pulmonary.
Median enrollment 30 across the 286 interventional studies, 108 across the 107 observational. Of the 273 that completed or were terminated, 139 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
158 of 397 have an industry lead sponsor. The 10 most frequent:
Insmed Incorporated is the lead sponsor of 50 studies on the registry; 8 are open to participants now.
Of its 28 completed or terminated interventional studies of FDA-regulated products, 8 (29%) have results posted.
Insmed Incorporated has 5 studies filed under Hypertension, Pulmonary — fewer than ten, so there is no comparison to draw.
21 of the studies in Hypertension, Pulmonary with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT06616974Tectonic TherapeuticA Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study) | 2026-11-24 |
| NCT07333183Pulmovant, Inc.A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD | 2026-12 |
| NCT05442671Children's Hospital of PhiladelphiaiTONE Trial (exercIse Training in pulmONary hypertEnsion) Exercise Program for Pediatric PH | 2026-12-31 |
| NCT04808596University of Kansas Medical CenterPulmonary Hypertension Biorepository and Registry | 2026-12-31 |
Add all 21 to your calendar (.ics) → With an account.
Among the 397 studies in Hypertension, Pulmonary with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the safety and tolerability of the long-term use of TPIP in participants with PH-ILD from Study INS1009-311 (NCT07179380).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Note: Other protocol-defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants transitioning from study INS1009-311 (NCT07179380) will undergo an initial double-dummy titration with the stable dose from the lead-in study and either TPIP or placebo for 4 weeks. They will then receive open-label TPIP at a stable maintenance dose with optional escalation (80-1280 micrograms once daily) for the remainder of the 104-week treatment period.
Drug: Treprostinil Palmitil Inhalation Powder · Drug: Placebo
Oral inhalation using a capsule-based dry powder.
Also known as: INS1009
Oral inhalation in initial double-dummy titration period.
Number of Participants Who Experienced at Least One Treatment-Emergent Adverse Events (TEAEs)
Time frame: Up to 108 weeks
Change From Baseline in 6-Minute Walk Distance (6MWD) Measured Post-Dose
Time frame: Up to 104 weeks
Absolute Change From Baseline in Forced Vital Capacity (FVC)
Time frame: Up to 104 weeks
Percent Change From Baseline in Forced Vital Capacity (FVC)
Time frame: Up to 104 weeks
Absolute Change From Baseline in Percent Predicted FVC (FVC% pred)
Time frame: Up to 104 weeks
Percent Change From Baseline in Percent Predicted FVC (FVC% pred)
Time frame: Up to 104 weeks
Absolute Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)
Time frame: Up to 104 weeks
Percent Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)
Time frame: Up to 104 weeks
Absolute Change From Baseline in Percent Predicted FEV1 (FEV1%)
Time frame: Up to 104 weeks
Percent Change From Baseline in Percent Predicted FEV1 (FEV1%)
Time frame: Up to 104 weeks
Change From Baseline in the Plasma Concentration of N-Terminal Pro B-Type Natriuretic Peptide (NT-proBNP)
Time frame: Up to 104 weeks
Annualized Rate of Occurrence of Exacerbations of Interstitial Lung Disease (ILD)
Time frame: Up to 104 weeks
Percentage of Participants With a Clinical Worsening Events
Time frame: Up to 104 weeks
Mean Change From Baseline in Living With Pulmonary Fibrosis (L-PF) Domain Score
Time frame: Up to 104 weeks
Mean Change From Baseline in L-PF Cough Domain Score
Time frame: Up to 104 weeks
Mean Change From Baseline in L-PF Dyspnea Domain Score
Time frame: Up to 104 weeks
Mean Change From Baseline in L-PF Impact Domain Score
Time frame: Up to 104 weeks
Mean Change From Baseline in the EuroQoL- 5 Dimensions (EQ-5D-5L) Index Score
Time frame: Up to 104 weeks
Mean Change From Baseline in the EQ-5D-5L Visual Analog Scale (VAS)
Time frame: Up to 104 weeks
Percentage of Participants With Major Morbidity or Mortality Events
Time frame: Up to 104 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2026 (actual). Primary completion is estimated for Jan 2031, 54 months after the start.
Of 31 phase 3 interventional studies under Hypertension, Pulmonary, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 83. This study's planned 54 months is close to that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Treprostinil hexadecyl ester